British Columbia Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-27,563
Closed -$1.49M 701
2025
Q3
$1.49M Sell
27,563
-2,624
-9% -$150K 0.01% 635
2025
Q2
$1.66M Sell
30,187
-6,251
-17% -$368K 0.01% 622
2025
Q1
$2.58M Sell
36,438
-10
-0% -$673 0.02% 568
2024
Q4
$2.4M Buy
36,448
+4,772
+15% +$320K 0.01% 594
2024
Q3
$2.23M Sell
31,676
-4,667
-13% -$390K 0.01% 591
2024
Q2
$2.99M Buy
36,343
+13,853
+62% +$1.15M 0.02% 516
2024
Q1
$1.96M Buy
22,490
+818
+4% +$73.2K 0.01% 566
2023
Q4
$2.09M Buy
21,672
+4,601
+27% +$407K 0.02% 510
2023
Q3
$1.51M Buy
17,071
+159
+0.9% +$14.1K 0.01% 509
2023
Q2
$1.47M Buy
16,912
+483
+3% +$45.5K 0.01% 541
2023
Q1
$1.6M Hold
16,429
0.02% 505
2022
Q4
$1.7M Sell
16,429
-1,876
-10% -$176K 0.02% 488
2022
Q3
$1.55M Sell
18,305
-2,920
-14% -$260K 0.02% 514
2022
Q2
$1.76M Sell
21,225
-7,118
-25% -$567K 0.02% 537
2022
Q1
$2.19M Sell
28,343
-3,837
-12% -$321K 0.01% 633
2021
Q4
$2.84M Sell
32,180
-1,616
-5% -$133K 0.02% 609
2021
Q3
$2.61M Buy
33,796
+188
+0.6% +$14.8K 0.02% 628
2021
Q2
$2.8M Buy
33,608
+3,860
+13% +$306K 0.02% 625
2021
Q1
$2.25M Sell
29,748
-830
-3% -$67.8K 0.02% 628
2020
Q4
$2.68M Sell
30,578
-785
-3% -$62.2K 0.02% 557
2020
Q3
$2.39M Buy
31,363
+2,545
+9% +$257K 0.02% 537
2020
Q2
$3.55M Buy
28,818
+9,170
+47% +$911K 0.04% 387
2020
Q1
$1.66M Sell
19,648
-22,641
-54% -$1.95M 0.03% 420
2019
Q4
$3.58M Buy
42,289
+1,307
+3% +$98.7K 0.03% 469
2019
Q3
$2.76M Sell
40,982
-9,976
-20% -$768K 0.03% 491
2019
Q2
$4.37M Buy
50,958
+2,369
+5% +$203K 0.04% 477
2019
Q1
$4.32M Sell
48,589
-11,600
-19% -$1.08M 0.04% 466
2018
Q4
$5.13M Buy
60,189
+5,854
+11% +$557K 0.05% 410
2018
Q3
$5.27M Sell
54,335
-19,770
-27% -$1.97M 0.06% 381
2018
Q2
$6.98M Sell
74,105
-20,071
-21% -$1.76M 0.06% 371
2018
Q1
$7.63M Sell
94,176
-23,408
-20% -$2.01M 0.06% 384
2017
Q4
$10.5M Buy
117,584
+7,517
+7% +$654K 0.07% 306
2017
Q3
$10.2M Buy
110,067
+3,771
+4% +$333K 0.08% 297
2017
Q2
$9.65M Buy
106,296
+8,104
+8% +$737K 0.08% 310
2017
Q1
$8.62M Sell
98,192
-3,621
-4% -$322K 0.07% 364
2016
Q4
$8.43M Buy
101,813
+13,635
+15% +$1.17M 0.07% 314
2016
Q3
$8.16M Sell
88,178
-12,725
-13% -$1.2M 0.08% 291
2016
Q2
$7.85M Hold
100,903
0.07% 319
2016
Q1
$8.32M Buy
100,903
+4,639
+5% +$377K 0.08% 297
2015
Q4
$10.1M Buy
96,264
+53,741
+126% +$5.61M 0.1% 241
2015
Q3
$4.48M Buy
42,523
+11,617
+38% +$1.55M 0.05% 397
2015
Q2
$4.23M Sell
30,906
-3,501
-10% -$434K 0.04% 442
2015
Q1
$4.29M Sell
34,407
-19,711
-36% -$2.09M 0.04% 441
2014
Q4
$4.89M Buy
54,118
+38,513
+247% +$3.2M 0.04% 424
2014
Q3
$1.13M Hold
15,605
0.01% 602
2014
Q2
$971K Buy
15,605
+7,174
+85% +$433K 0.01% 622
2014
Q1
$575K Sell
8,431
-15,657
-65% -$1.15M ﹤0.01% 661
2013
Q4
$1.7M Sell
24,088
-56,115
-70% -$3.81M 0.01% 572
2013
Q3
$5.79M Buy
80,203
+69,152
+626% +$4.6M 0.05% 408
2013
Q2
$616K Buy
+11,051
New +$689K 0.01% 652

Other funds holding BMRN

British Columbia Investment Management's BMRN Position: Q4 2025 in Review

British Columbia Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 27,563 shares — an estimated $1.49M sold.

British Columbia Investment Management first reported a position in BMRN in Q2 2013 and held it in 50 quarters. The position peaked at $10.5M in Q4 2017. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • British Columbia Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • British Columbia Investment Management sold 27,563 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.49M.
  • British Columbia Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • British Columbia Investment Management's BioMarin Pharmaceuticals position peaked at $10.5M in Q4 2017.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on British Columbia Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.